meglumine antimoniate has been researched along with Disease Exacerbation in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, N; Boui, M; Frikh, R; Hjira, N; Lamsyah, H; Marcil, T; Oumakhir, S | 1 |
| Cruz, I; Flores, MD; López-Vélez, R; Mateo, M | 1 |
| Abdi, K; Darabi, M; Ghareghozloo, B; Kariminia, A; Solgi, G | 1 |
| Akrout, F; Ayadi, N; Bouassida, S; Boudaya, S; Khabir, A; Masmoudi, A; Meziou, TJ; Sallemi, T; Turki, H; Zahaf, A | 1 |
| Evans, TG; Hibbs, JB; Reed, SS | 1 |
| Alunda, JM; Cuquerella, M; de la Fuente, C; Fernández-Pérez, FJ; Gómez, MT; Méndez, S | 1 |
6 other study(ies) available for meglumine antimoniate and Disease Exacerbation
| Article | Year |
|---|---|
[Clinical, epidemiological and evolutionary aspects in 157 cases of cutaneous leishmaniasis in Morocco].
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Cicatrix; Disease Progression; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Morocco; Nitrogen; Organometallic Compounds; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
[Slowly progressing skin ulcers following a stay in Costa Rica].
Topics: Adult; Animals; Antiprotozoal Agents; Costa Rica; Disease Progression; DNA, Protozoan; Facial Dermatoses; Hand Dermatoses; Humans; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Polymerase Chain Reaction; RNA, Protozoan; RNA, Ribosomal; Skin Ulcer; Spain; Travel | 2005 |
Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Female; Immunosuppressive Agents; Interferon-gamma; Interleukin-10; Interleukin-12; Leishmania major; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Thalidomide; Time Factors | 2006 |
[Clinical and histological study of lupoid cutaneous leishmaniasis (16 cases)].
Topics: Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Biopsy; Child; Disease Progression; Female; Follow-Up Studies; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Skin; Time Factors; Treatment Outcome | 2007 |
Nitric oxide production in murine leishmaniasis: correlation of progressive infection with increasing systemic synthesis of nitric oxide.
Topics: Animals; Antiprotozoal Agents; Body Weight; Disease Progression; Injections, Intraperitoneal; Leishmaniasis; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Nitric Oxide; Organometallic Compounds; Species Specificity | 1996 |
Value of Western blotting in the clinical follow-up of canine leishmaniasis.
Topics: Allopurinol; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Blotting, Western; Disease Progression; Dog Diseases; Dogs; Enzyme Inhibitors; Fluorescent Antibody Technique, Indirect; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Sensitivity and Specificity; Treatment Outcome | 1999 |